Abstract
This study highlights that a novel p38-ATF6-mediated AP-1 signaling axis contributes to PARPi resistance and provides a clinical rationale for combining PARPi and AP-1 signaling inhibitors.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have